Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Studies in rodents have implicated various cytokines as paracrine mediators of increased osteoclastogenesis during estrogen deficiency, but increases in RANKL, the final effector of osteoclastogenesis, have not been demonstrated. Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe. The cells were characterized as preosteoblastic marrow stromal cells (MSCs), T lymphocytes, or B lymphocytes by using Ab's against bone alkaline phosphatase (BAP), CD3, and CD20, respectively, in 12 premenopausal women (Group A), 12 early postmenopausal women (Group B), and 12 age-matched, estrogen-treated postmenopausal women (Group C). Fluorescence intensity of OPG-Fc-FITC, an index of the surface concentration of RANKL per cell, was increased in Group B over Groups A and C by two- to threefold for MSCs, T cells, B cells, and total RANKL-expressing cells. Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell types and inversely with serum 17beta-estradiol for total RANKL-expressing cells. The data suggest that upregulation of RANKL on bone marrow cells is an important determinant of increased bone resorption induced by estrogen deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, estrogen deficiency is associated with an expansion of RANKL-and TNF-expressing T cells and B cells (27,28,30,31).”
From Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics (2016) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“RANKL levels were increased on the surface of bone marrow cells from early postmenopausal women who are estrogen deficient”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [48]
In the citing paper
“Moreover, estrogen stimulates these bone cells to produce osteoprotegerin (OPG), a decoy receptor of RANK in osteoclast, thus inhibiting osteoclastogenesis [19, 155–159].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [157]
In the citing paper
“In humans, estrogen deficiency is associated with increased RANKL expression by bone marrow osteoblastic, T and B cells, whereas estrogen treatment reversed this increase ( 76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
In the citing paper
“flow cytometry studies conducted with bone marrow aspirates from postmenopausal subjects showed that saturating levels of OPG did not reduce the ability of anti-TRAIL antibodies to recognize TRAIL-positive cells (76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“The expression of RANKL by T cells may be related, in part, to their function as immunoregulators, because targeted disruption of the RANKL gene results in mice lacking lymph nodes and with defective T and B lymphocyte differentiation (45).”
BackgroundSelf-citationManolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“For example, ERα knockout mice have short limbs and mild osteopenia (31), whereas a young adult male with homozygous null mutations of ERα had elongated limbs and a greater degree of osteopenia (32).”
BackgroundSuda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · cited 1×
“In an experimental mouse model of inflammatory arthritis, activated T lymphocytes expressing RANKL were shown to regulate the associated periarticular bone loss and joint destruction (46).”
BackgroundSelf-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Self-citation
Research works printed but not linked: 8
- 10.1210/jc.87.4.1443 · doi:10.1210/jc.87.4.1443 · Paper page
- 10.1210/en.142.12.5050 · doi:10.1210/en.142.12.5050 · Paper page
- 10.1210/en.140.9.4367 · doi:10.1210/en.140.9.4367 · Paper page
- 10.1210/en.142.6.2205 · doi:10.1210/en.142.6.2205 · Paper page
- 10.1210/jc.87.4.1550 · doi:10.1210/jc.87.4.1550 · Paper page
- 10.1210/en.141.12.4768 · doi:10.1210/en.141.12.4768 · Paper page
- Owen, 1988, Ciba Found. Symp., 136, 42
- 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6 · DOI
Cited by
Items 201–300 of 821
The Role of IL-17 and TH17 Cells in the Bone Catabolic Activity of PTH
Pacifici, R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00057 · Cited by 69
“For example, evidence begins to emerge in favor of a role of T cell produced TNF in postmenopausal bone loss in women (58, 59) and that in humans estrogen deficiency expands RANKL-expressing T cells and B cells (60, 61).”
BackgroundPostmenopausal osteoporosis, T cells, and immune dysfunction
Teitelbaum, S. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407335101 · Cited by 68
Postmenopausal Osteoporosis: A Literature Review
Bhatnagar, A., & Kekatpure, A. L. (2022) · Cureus · doi:10.7759/cureus.29367 · Cited by 106
“, which reported an elevated expression of RANKL on bone marrow cells such as lymphocytes and osteoblasts in women with postmenopausal osteoporosis as compared to premenopausal control subjects [55].”
Prevention, Screening, and Management of Osteoporosis: An Overview of the Current Strategies
Bonura, F. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2021 · Cited by 77
Widschwendter, M., Burnell, M., Fraser, L., Rosenthal, A. N., Philpott, S., Reisel, D., Dubeau, L., Cline, M., Pan, Y., Yi, P.-C., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.037 · Cited by 65
“However, serum levels of RANKL do not appear to reflect local increases at the tissue level, including breast (this study) and bone (Eghbali-Fatourechi et al., 2003).”
BackgroundThe RANKL-RANK Axis: A Bone to Thymus Round Trip
Sobacchi, C., Menale, C., & Villa, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00629 · Cited by 64
“In post-menopausal osteoporotic patients an increase in RANKL production by activated T cells (and B cells, too), alone or in combination with TNFα, has been reported (111, 112).”
BackgroundLi, D., Hitchcock, C. L., Barr, S. I., Yu, T., & Prior, J. C. (2014) · Epidemiologic Reviews · doi:10.1093/epirev/mxt012 · Cited by 63
Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results
Palmerini, E., Ruggieri, P., Angelini, A., Boriani, S., Campanacci, D. A., Milano, G. M., Cesari, M., Paioli, A., Longhi, A., Abate, M. E., et al. (2018) · Tumori Journal · doi:10.1177/0300891618784808 · Cited by 65
Bone-Immune Cell Crosstalk: Bone Diseases
Mori, G., D’Amelio, P., Faccio, R., & Brunetti, G. (2015) · Journal of Immunology Research · doi:10.1155/2015/108451 · Cited by 69
“increases in bone resorption markers and inversely with serum estrogen levels [77].”
BackgroundEffect of Endocrine Therapies on Bone in Breast Cancer Patients
Santen, R. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1679 · Cited by 74
The multi-faceted nature of age-associated osteoporosis
Smit, A. E., Meijer, O. C., & Winter, E. M. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101750 · Cited by 94
Pharmacological management of osteogenesis
Nardone, V., D’Asta, F., & Brandi, M. L. (2014) · Clinics · doi:10.6061/clinics/2014(06)12 · Cited by 67
“In postmenopausal women, the deficiency of estrogen leads to an upregulation of RANKL on bone marrow cells, resulting in an increase in bone resorption (70).”
BackgroundMedicamentos para o tratamento da osteoporose: revisão
Khajuria, D. K., Razdan, R., & Mahapatra, D. R. (2011) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042011000400008 · Cited by 138
RANK ligand and the regulation of skeletal remodeling
Bell, N. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18358 · Cited by 77
Yoneda, T., Ishimaru, N., Arakaki, R., Kobayashi, M., Izawa, T., Moriyama, K., & Hayashi, Y. (2004) · Endocrinology · doi:10.1210/en.2003-1536 · Cited by 60
Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures
Abdallah, B. M., Stilgren, L. S., Nissen, N., Kassem, M., Jørgensen, H. R. I., & Abrahamsen, B. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0074-4 · Cited by 60
“In accordance with this, a positive correlation has been reported between bone resorption markers and the extent of RANKL expression on the surface of bone marrow cells in postmenopausal women [5].”
BackgroundQiu, S. X., Dan, C., Ding, L., Peng, S., Chen, S., Farnsworth, N. R., Nolta, J. A., Gross, M. L., & Zhou, P. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.06.010 · Cited by 68
“Despite a variety of mechanisms through which estrogen deficiency induces bone loss, upregulation of the osteoclastogenic cytokines RANKL and TNFa plays a significant role [31, 32].”
BackgroundRole of the RANK/RANKL pathway in breast cancer
Kiesel, L., & Kohl, A. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.01.001 · Cited by 67
Iseri, K., Iyoda, M., Watanabe, M., Matsumoto, K., Sanada, D., Inoue, T., Tachibana, S., & Shibata, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193846 · Cited by 66
Associations Among Estrogens, the Gut Microbiome and Osteoporosis
Kverka, M., & Stepan, J. J. (2024) · Current Osteoporosis Reports · doi:10.1007/s11914-024-00896-w · Cited by 76
“Decreased secretion of osteoprotegerin by osteo-cytes, as well as B cells and dendritic cells [112], prevents the interaction between RANKL and RANK and contributes to increased osteoclastogenesis and prolongation of the lifespan of osteoclasts [107].”
Estrogen therapy for postmenopausal osteoporosis
Fitzpatrick, L. A. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000400016 · Cited by 63
“Overall this study indicates that RANKL, a final effector of osteoclast formation and function is increased by estrogen deficiency and decreased by estrogen sufficiency in bone marrow cells, implicating the critical role of estrogen in the pathogenesis of postmenopausal osteoporosis (12).”
BackgroundTaxel, P., Kaneko, H., Lee, S.-K., Aguila, H. L., Raisz, L. G., & Lorenzo, J. A. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0452-7 · Cited by 58
“Similar to our own findings, they demonstrated that RANKL levels were increased on the surface of bone marrow cells of early postmenopausal women compared to premenopausal women or postmenopausal women on estrogen [7].”
ResultRANK ligand inhibition with denosumab for the management of osteoporosis
Lewiecki, E. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1041 · Cited by 65
“Flow cytometry of bone marrow cells of pre- and postmenopausal women showed upregulation of RANKL after menopause [25], which is consistent with RANKL playing a role in high bone turnover and bone loss commonly associated with this population.”
ResultAlghamdi, H. S., & Jansen, J. A. (2012) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2012.0400 · Cited by 68
“86,92 Osteoclasts are large bone cells of about 40 m m in diameter and contain * 15–20 oval-shaped nuclei.”
Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis
Jules, J., Ashley, J. W., & Feng, X. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.511179 · Cited by 63
“Thus, targeting the RANKL/RANK/OPG system should produce potent effects on osteoclast differentiation and function; ii) It has been shown that RANKL expression is elevated in the bone marrow cells of postmenopausal women (Figure 1) [50].”
BackgroundLuvizuto, E. R., Queiroz, T. P., Dias, S. M. D., Okamoto, T., Dornelles, R. C. M., Júnior, I. R. G., & Okamoto, R. (2009) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2009.11.001 · Cited by 83
Bilezikian, J. P., Matsumoto, T., Bellido, T., Khosla, S., Martin, J. W., Recker, R. R., Heaney, R. P., Seeman, E., Papapoulos, S. E., & Goldring, S. R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090105 · Cited by 62
“with an increase in RANKL production by bone marrow osteoblastic, T, and B cells.((62)) More prolonged sex steroid deficiency is associated with an increase in osteoblasto-”
BackgroundInfluentialSelf-citationLei, S., Wu, S., Li, L.-M., Deng, F., Xiao, S., Jiang, C., Chen, Y., Jiang, H., Yang, F., Tan, L., et al. (2008) · Bone · doi:10.1016/j.bone.2008.05.016 · Cited by 59
Myokines and Osteokines in the Pathogenesis of Muscle and Bone Diseases
Colaianni, G., Storlino, G., Sanesi, L., Colucci, S. C., & Grano, M. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00600-8 · Cited by 66
Mohd Effendy, N., Mohamed, N., Muhammad, N., Naina Mohamad, I., & Shuid, A. N. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/125761 · Cited by 55
“Estrogen is able to suppress RANKL production by osteoblast-lineage cells and T and B cells [56], which consequently causes the inhibition of bone resorption by osteoclasts.”
BackgroundRoato, I., Porta, F., Mussa, A., D’Amico, L., Fiore, L., Garelli, D., Spada, M., & Ferracini, R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014167 · Cited by 58
“The main cytokines involved in the regulation of OC differentiation and function have been defined: macrophage colony stimulating factor (M-CSF) induces the proliferation and differentiation of OCPs; receptor activator of nuclear factor kB ligand (RANKL) promotes OC activity and decreases their apoptosis [19]; osteopr…”
BackgroundB Cell Production of Both OPG and RANKL is Significantly Increased in Aged Mice
N. Weitzmann, M., Li, Y., Terauchi, M., Vikulina, T., & Roser-Page, S. (2015) · The Open Bone Journal · doi:10.2174/1876525401406010008 · Cited by 53
“B cells have however been observed to secrete RANKL and may directly contribute to bone loss when activated as occurs in several pathological conditions including estrogen deficiency [28, 29], periodontal infection [30, 31], psoriatic arthritis [32] and HIV infection [9, 10].”
BackgroundThe effect of vitamin K2 on bone metabolism in aged female rats
Sakamoto, W., Isomura, H., Fujie, K., Iizuka, T., Nishihira, J., Tatebe, G., Takahashi, K., Osaki, Y., Komai, M., & Tamai, H. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1881-9 · Cited by 55
“Direct effects on osteoclasts [2], upregulation of the osteoclast-inductive cytokine RANKL (osteoclast activating factor) [3] and downregulation of its decoy receptor osteoprotegrin in osteoblasts [4] have been reported.”
BackgroundKarsdal, M. A., Bay‐Jensen, A., Henriksen, K., & Christiansen, C. (2012) · Menopause international · doi:10.1258/mi.2012.012025 · Cited by 61
Update on Menopausal Hormone Therapy for Fracture Prevention
Stepan, J. J., Hruskova, H., & Kverka, M. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00549-3 · Cited by 65
The Circadian Rhythm of Osteoprotegerin and Its Association with Parathyroid Hormone Secretion
Joseph, F., Chan, B. Y., Durham, B. H., Ahmad, A. M., Vinjamuri, S., Gallagher, J. A., Vora, J. P., & Fraser, W. D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1832 · Cited by 55
Zhao, H., Zhao, N., Zheng, P., Xu, X., Liu, M., Luo, D., Xu, H., & Ju, D. (2018) · Journal of Immunology Research · doi:10.1155/2018/6345857 · Cited by 56
“An ethanol extract of Eucommia ulmoides relieved arthritis degradation via inhibition of the key proinflammatory cytokines TNF-α, IL17, and IL-1β and increases the antiinflammatory effects of IL-10 [107].”
BackgroundInfluentialWang, X., Yamauchi, K., & Mitsunaga, T. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104482 · Cited by 54
New treatment targets in osteoporosis
Roux, S. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.02.004 · Cited by 62
González-Calvin, J. L., Mundi, J. L., Casado-Caballero, F. J., Abadia, A. C., & Martin-Ibañez, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0835 · Cited by 53
“RANKL, expressed on the surface of preosteoblastic/stromal cells and osteoblasts, has been identified as the key mediator of osteoclastogenesis by binding to its receptor RANK, which is expressed on the surface of osteoclastlineage cells (18).”
BackgroundInfluentialIs Cortical Bone Hip? What determines Cortical Bone Properties?
Epstein, S. (2007) · Bone · doi:10.1016/j.bone.2007.03.006 · Cited by 53
“Anabolic treatments, such as PTH and strontium ranelate, have proved their efficacy in improving both cortical and cancellous bone structures [31].”
BackgroundOsteoblast ontogeny and implications for bone pathology: an overview
Titorencu, I. D., Prună, V., Jinga, V. V., & Simionescu, M. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1750-3 · Cited by 62
“In early postmenopausal women, the RANKL level is increased on the surface of bone marrow cells in response to the low oestrogens concentration (Eghbali-Fatourechi et al. 2003).”
BackgroundReengineering autologous bone grafts with the stem cell activator WNT3A
Wei, J., Smith, A. A., Liu, B., Li, J., Hunter, D. J., Dhamdhere, G. R., Salmon, B. J. R., Jiang, J., Cheng, D., Johnson, C. A., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.014 · Cited by 51
Commitment to the Osteoblast Lineage Is Not Required for RANKL Gene Expression
Galli, C., Fu, Q., Wang, W., Olsen, B. R., Manolagas, S. C., Jilka, R. L., & O'Brien, C. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806628200 · Cited by 51
Jia, J., Zhou, H., Zeng, X., & Feng, S. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6168 · Cited by 55
“Eghbali‑Fatourechi et al (8) reported that upregulation of RANKL in bone marrow cells is an important determinant of increased bone resorption induced by estrogen deficiency in postmenopausal women.”
Cui, J., Li, X., Wang, S., Su, Y., Chen, X., Cao, L., Zhi, X., Qiu, Z., Wang, Y., Jiang, H., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15229 · Cited by 51
Targeting RANKL in breast cancer: bone metastasis and beyond
Azim, H. A., & Azim, H. A. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.177 · Cited by 51
Telomere length and telomerase activity in osteoporosis and osteoarthritis (Review)
Fragkiadaki, P., Nikitovic, D., Kalliantasi, K., Sarandi, E., Thanasoula, M., Stivaktakis, P. D., Nepka, C., Spandidos, D. A., Theodoros, T., & Tsatsakis, A. M. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8370 · Cited by 69
“Moreover, the ability of estrogens to downregulate receptor activator of nuclear factor-κΒ ligand (RANKL) synthesis has been shown in osteoblasts and likewise in T- and B-cells (16).”
BackgroundBrent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 55
D’Amelio, P., Roato, I., D’Amico, L., Veneziano, L., Suman, E., Sassi, F., Bisignano, G., Ferracini, R., Gargiulo, G., Castoldi, F., et al. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1496-7 · Cited by 50
“This result is in keeping with the well-known effect of aging on bone loss due to a progressive increase in osteoclast formation and activity [5, 9].”
BackgroundResultInfluentialMartin, A., Xiong, J., Koromila, T., Ji, J. S., Chang, S. W., Song, Y. S., Miller, J. L., Han, C.-Y. E., Kostenuik, P. J., Krum, S. A., et al. (2015) · Bone · doi:10.1016/j.bone.2015.02.007 · Cited by 53
“As a result, RUNX2-driven RANKL trafficking to the surface of bone marrow pre-osteoblasts [35] could engage its receptor, RANK, on neighboring monocytic cells to promote osteoclast differentiation.”
BackgroundResultSkeletal and extraskeletal actions of denosumab
Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 55
Denosumab for the Reduction of Bone Loss in Postmenopausal Osteoporosis: A Review
Bridgeman, M. B., & Pathak, R. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.008 · Cited by 51
Adeel, S., Singh, K., Vydareny, K. H., Kumari, M., Shah, E., Weitzmann, M. N., & Tangpricha, V. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0000000000000016 · Cited by 48
“Very few clinical studies have been conducted to establish a central role for T lymphocytes in postmenopausal osteoporosis (22,23,24,25).”
BackgroundVinik, Y., Shatz‐Azoulay, H., Vivanti, A., Hever, N., Levy, Y. A., Karmona, R., Brumfeld, V., Baraghithy, S., Attar-Lamdar, M., Boura‐Halfon, S., et al. (2015) · eLife · doi:10.7554/elife.05914 · Cited by 49
“Given that RANKL is both necessary and sufficient for osteoclast differentiation, provided that permissive concentrations of MCSF are present (Eghbali-Fatourechi et al., 2003), and given that galectin-8 does not affect the expression of MCSF, our findings strongly suggest that RANKL mediates the…”
BackgroundNeuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat
Zengin, A., Zhang, L., Herzog, H., Baldock, P. A. J., & Sainsbury, A. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.02.004 · Cited by 55
Ulrich‐Vinther, M. (2007) · Acta Orthopaedica · doi:10.1080/17453690610046512 · Cited by 51
UV-Photofunctionalization of Titanium Promotes Mechanical Anchorage in A Rat Osteoporosis Model
Taniyama, T., Saruta, J., Rezaei, N. M., Nakhaei, K., Ghassemi, A., Hirota, M., Okubo, T., Ikeda, T., Sugita, Y., Hasegawa, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041235 · Cited by 49
“Estrogen suppresses RANKL production by osteoblasts, T cells, and B cells [25].”
BackgroundChen, C.-P., Huang, J.-P., Chu, T.-Y., Aplin, J., Chen, C.-Y., & Wu, Y.-H. (2013) · Placenta · doi:10.1016/j.placenta.2013.06.311 · Cited by 47
“Alterations of integrin abundance on the cell surface were evaluated by fluorescence intensity, an index of the surface concentration of integrin per cell [30].”
BackgroundEstrogen and bone: Insights from estrogen-resistant, aromatase-deficient, and normal men
Khosla, S. (2008) · Bone · doi:10.1016/j.bone.2008.05.005 · Cited by 52
Self-citationOsteoblast Role in Rheumatic Diseases
Corrado, A., Maruotti, N., & Cantatore, F. P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061272 · Cited by 49
Fayed, H. A., Barakat, B. M., Elshaer, S. S., Abdel‐Naim, A. B., & Menze, E. T. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172785 · Cited by 48
Abe, Y., Chiba, M., Yaklai, S., Pechayco, R. S., Suzuki, H., & Takahashi, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-56484-x · Cited by 49
Gambari, L., Grassi, F., Roseti, L., Grigolo, B., & Desando, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176001 · Cited by 49
“Excessive ROS production is among the most frequent pathological aspects of the skeletal involution following ageing and loss of sex steroids [101,102].”
BackgroundNakchbandi, I. A., Lang, R., Kinder, B. K., & Insogna, K. L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1645 · Cited by 54
“Consistent with this idea, bone marrow cells from estrogen-deficient postmenopausalwomenexpresshigherlevelsofcellsurfaceRANKL ( 32 ).”
BackgroundVoorzanger‐Rousselot, N., Journé, F., Doriath, V., Body, J., & Garnero, P. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9225-y · Cited by 46
“This situation is reminiscent of the poor and nonconsistent association between circulating OPG and the receptor activator of nuclear factor jB ligand (RANKL) with biochemical markers of bone turnover and bone mineral density [32], although when measured in the bone marrow high correlations can be observed [33].”
BackgroundLi, C., Lin, X., Lin, Y., Lin, Y., & Lin, H. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155137 · Cited by 49
Yin, L., Sun, C., Zhang, J., Li, Y., Wang, Y., Bai, L., & Lei, Z. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1639430 · Cited by 57
“This mechanism is particularly evident in postmenopausal women, as the decline in estrogen levels leads to an imbalance in bone remodeling, increased bone resorption and reduced bone formation (Khosla and Riggs, 2005; Eghbali-Fatourechi et al., 2003).”
Wei, Q., Huang, L., Tan, X., Chen, Z., Chen, S., & Deng, W. (2015) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2015.1087045 · Cited by 44
“postmenopausal women were demonstrated [25,26].”
Alamir, M. A., Radulescu, V., Goyfman, M., Mohler, E. R., Gao, Y. L., & Budoff, M. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.013 · Cited by 44
“Estrogen plays an important part in bone density regulation by inducing osteoclast apoptosis, inhibiting osteoclast formation and differentiation from monocytes, increases OPG production, decreasing RANKL production, decreasing IL-1, IL-6, TNFα formation, inhibiting osteoblast apoptosis, and increasing osteoblast life…”
BackgroundAbrahamsen, B., Hjelmborg, J., Kostenuik, P. J., Stilgren, L. S., Kyvik, K. O., Adamu, S., Brixen, K., & Langdahl, B. L. (2005) · Bone · doi:10.1016/j.bone.2004.12.015 · Cited by 49
Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG)
Hofbauer, L. C. (2006) · Annales d Endocrinologie · doi:10.1016/s0003-4266(06)72569-0 · Cited by 47
“Marrow stromal cells and lymphocytes from postmenopausal women display higher levels of RANKL expression than premenopausal women or postmenopausal women on estrogen replacement therapy [6].”
BackgroundXu, S., Zhang, Y., Liu, B., Li, K., Huang, B., Yan, B., Zhang, Z., Liang, K., Jia, C., Lin, J., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2800 · Cited by 44
Reduced Osteoclastogenesis and RANKL Expression in Marrow from Women Taking Alendronate
Eslami, B., Zhou, S., van Eekeren, I. C. M., LeBoff, M. S., & Glowacki, J. (2011) · Calcified Tissue International · doi:10.1007/s00223-011-9473-5 · Cited by 44
“[43] noted that expression of RANKL in MSCs, as well as in marrow-derived T and B cells, was related to bone turnover, age, and estrogen status of the subject.”
BackgroundOsteoimmunology: from mice to humans
D’Amelio, P., & Sassi, F. (2016) · bonekey Reports · doi:10.1038/bonekey.2016.29 · Cited by 43
“RANKL directly correlates with increase in bone resorption markers and inversely with serum estrogen levels.(37)”
BackgroundEffects of cod bone gelatin on bone metabolism and bone microarchitecture in ovariectomized rats
Han, X., Xu, Y., Wang, J., Pei, X., Yang, R., Li, N., & Li, Y. (2008) · Bone · doi:10.1016/j.bone.2008.12.005 · Cited by 48
“Postmenopausal osteoporosis associated with an imbalance in the RANKL/OPG system in favor of RANKL [10].”
BackgroundThe role of endocrine hormones in the pathogenesis of adolescent idiopathic scoliosis
Liang, Z., Guo, C., Li, J., & Zhang, H. (2021) · The FASEB Journal · doi:10.1096/fj.202100759r · Cited by 50
Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats
Proell, V., Xu, H., Schüler, C., Weber, K., Hofbauer, L. C., & Erben, R. G. (2009) · Bone · doi:10.1016/j.bone.2009.05.024 · Cited by 45
“membrane expression of RANKL protein on alkaline phosphatasepositive osteoblastic cells, CD3-positive T cells, and CD20-positive B cells [23].”
BackgroundThe hidden secrets of soluble RANKL in bone biology
Elango, J., Bao, B., & Wu, W. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155559 · Cited by 50
Muscle-Bone Crosstalk in Chronic Obstructive Pulmonary Disease
Zhang, L., & Sun, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.724911 · Cited by 52
“In postmenopausal women, the elevated expression of RANKL plays a pivotal role in the development of osteoporosis (63).”
BackgroundXu, D., Wang, S., Liu, W., Liu, J., & Feng, X. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510383200 · Cited by 42
Sato, T., Watanabe, K., Masuhara, M., Hada, N., & Hakeda, Y. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0723-y · Cited by 41
“pausal women has been demonstrated [17].”
Jules, J., Shi, Z., Liu, J., Xu, D., Wang, S., & Feng, X. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149484 · Cited by 45
Therapeutic implications of osteoprotegerin
Fili, S., Karalaki, M., & Schaller, B. J. (2009) · Cancer Cell International · doi:10.1186/1475-2867-9-26 · Cited by 48
“Recent studies have shown that the up-regulation of RANKL on bone marrow cells induced by estrogen deficiency in postmenopausal women is responsible for the bone resorption [47].”
BackgroundSafety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2011) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s7727 · Cited by 41
“25 Recombinant OPG prevents bone loss in ovariectomized rats 25 and causes nonlethal osteopetrosis in normal mice.”
InfluentialDenosumab for bone diseases: translating bone biology into targeted therapy
Tsourdi, E. A., Rachner, T. D., Rauner, M., Hamann, C., & Hofbauer, L. C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0454 · Cited by 46
Saha, H., Mukherjee, B., Bindhani, B., & Ray, M. R. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3275 · Cited by 42
“T-lymphocytes are involved in the bone loss in postmenopausal women (Eghbali-Fatourechi et al., 2003) and in ovariectomized mice (Pacifici, 2012) via increased production of TNF-α and RANKL (Onal et al.”
BackgroundResultA practical guide for evaluating the osteoimmunomodulatory properties of biomaterials
Mestres, G., Carter, S. D., Hailer, N. P., & Díez-Escudero, A. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.038 · Cited by 43
“Physiological bone turnover can be hampered by several diseases which mainly involve an altered activity of immune or skeletal cells such as osteoporosis, hyperparathyroidism, and immune diseases [14–18] .”
BackgroundSilvio, L. D., Jameson, J., Gamie, Z., Giannoudis, P. V., & Tsiridis, E. E. (2006) · Injury · doi:10.1016/j.injury.2006.08.022 · Cited by 41
Ross, F. P., & Christiano, A. M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28605 · Cited by 55
Gomes‐Filho, J. E., Wayama, M. T., Dornelles, R. C. M., Ervolino, E., Yamanari, G. H., Lodi, C. S., Sivieri‐Araújo, G., Dezan‐Júnior, E., & Cintra, L. T. Â. (2014) · International Endodontic Journal · doi:10.1111/iej.12403 · Cited by 44
RANKL/RANK/OPG system and bone status in females with anorexia nervosa
Ostrowska, Z., Ziora, K. T., Oświęcimska, J. M., Świętochowska, E., Szapska, B., Wołkowska-Pokrywa, K., & Dyduch, A. (2011) · Bone · doi:10.1016/j.bone.2011.09.054 · Cited by 39
Dong, S.-S., Liu, X.-G., Chen, Y., Guo, Y., Wang, L., Zhao, J., Xiong, D. H., Xu, X.-H., Recker, R. R., & Deng, H. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9255-5 · Cited by 40
“[40] reported that upregulation of RANKL in bone marrow cells can promote bone resorption, providing biological support for a functional role of RANKL in bone remodeling.”
Bashir, A. A., Mak, Y. T., Sankaralingam, S., Cheung, J., Nwa., M., Grigoriadis, A. E., Fogelman, I., & Hampson, G. (2005) · Steroids · doi:10.1016/j.steroids.2005.04.011 · Cited by 43
Gossiel, F., Hoyle, C., McCloskey, E. V., Naylor, K. E., Walsh, J., Peel, N. F. A., & Eastell, R. (2016) · Bone · doi:10.1016/j.bone.2016.08.010 · Cited by 47
Nicks, K. M., Fujita, K., Fraser, D., McGregor, U., Drake, M. T., McGee-Lawrence, M. E., Westendorf, J. J., Monroe, D. G., & Khosla, S. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2723 · Cited by 38
“Because previous studies have indicated that estrogen may alter expression of several key mediators of bone metabolism, including tnfrsf11b (OPG),((24)) tnfsf11 (RANKL),((25)) sost,((15)) and sclerostin domain-containing 1 (sostdc1),((26)) we specifically examined possible changes in these genes in the ERb”
BackgroundSelf-citationTitanji, K., Vunnava, A., Foster, A., Sheth, A. N., Lennox, J. L., Knežević, A., Shenvi, N. V., Easley, K. A., Ofotokun, I., & Weitzmann, M. N. (2018) · AIDS · doi:10.1097/qad.0000000000001764 · Cited by 43
“osteoporosis [12], and periodontal infection [7,13].”
BackgroundMethodPost-menopausal Osteoporosis and Probiotics
Huidrom, S., Beg, M. A., & Masood, T. (2020) · Current Drug Targets · doi:10.2174/1389450121666201027124947 · Cited by 53
Pathophysiology of Vascular Calcification and Bone Loss: Linked Disorders of Ageing?
Cannata-Andía, J. B., Carrillo‐López, N., Messina, O. D., Hamdy, N. A. T., Panizo, S., Ferrari, S., & On Behalf Of The International Osteoporosis Foundation Iof Working Group On Bone And Cardiovascular Diseases (2021) · Nutrients · doi:10.3390/nu13113835 · Cited by 45
“Loss of estrogen during menopause leads to an increased expression of RANKL [40] and a decreased expression of osteoprotegerin (OPG), its natural antagonist, by bone cells (including osteoblasts, osteocytes and T lymphocytes), thereby increasing bone resorption in all compartments [39].”
BackgroundColaianni, G., Sun, L., Zaidi, M., & Zallone, A. Z. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00040.2014 · Cited by 47
“In addition to direct effects on osteoclasts, estrogen also appears to indirectly regulate osteoclast formation and activity, suppressing RANKL production by osteoblastic, T and B cells (21).”
Metadata
- Authors
- Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L.
- Affiliations
- Mayo Clinic (US)
- Amgen (United States) (US)
- Corresponding author
- Riggs, B. Lawrence
- Venue
- Journal of Clinical Investigation
- Published
- 2003-04-15
- Volume
- 111
- Issue
- 8
- Pages
- 1221-1230
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC152939
- OpenAlex
- W4254761345
- Cited by
- 825
- References
- 44
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 28 · 2023: 25 · 2022: 34 · 2021: 36 · 2020: 41 · 2019: 30 · 2018: 39 · 2017: 39 · 2016: 33 · 2015: 45 · 2014: 31 · 2013: 42 · 2012: 52
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- National Institutes of Health (M01-RR00 585, AG 04875, RR-00585)
- U.S. Public Health Service (AG-04875)
- National Institute on Aging (P01-AG04875, P01AG004875)
- National Center for Research Resources (M01-RR00 585, M01RR000585)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- RANK ligand, bone resorption, postmenopausal osteoporosis, estrogen deficiency, osteoclastogenesis, mesenchymal stem cells, T cells, B cells, osteoprotegerin, estradiol, bone turnover markers, paracrine signaling
- MeSH terms
- Adult, Bone Resorption, Carrier Proteins, Female, Flow Cytometry, Glycoproteins, Humans, Membrane Glycoproteins, Middle Aged, Tumor Necrosis Factor-alpha, Osteoporosis, Postmenopausal, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Apoptosis Regulatory Proteins, TNF-Related Apoptosis-Inducing Ligand, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.